New meningitis vaccine shows promise for infants in phase 3 trial
NCT ID NCT05093829
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine (NmCV-5) to protect infants against meningitis, a serious infection of the brain and spine. About 1,325 healthy infants in Mali received either the new vaccine or a standard one at 9 or 15 months old. The goal was to see if the new vaccine works as well as the current vaccine and is safe when given with routine shots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre pour le Developpement des Vaccins du Mali
Bamako, Mali
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can talk therapy tame brain Injury's emotional storm?
- Oral vs. needle: which stops Kids' seizures faster?
- Could a Mitochondria-Boosting supplement beat multivitamins for preventing colds?
- Scientists probe how meningitis vaccines spark immunity
- Massive meningitis study aims to improve care in brazil
- Massive study tracks meningitis trends in 10,000 kids